Skip to Content

Celcuity Inc CELC

Morningstar Rating
$14.89 +0.28 (1.92%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CELC is trading at a 192% premium.
Price
$14.84
Fair Value
$67.32
Uncertainty
Extreme
1-Star Price
$622.68
5-Star Price
$7.64
Economic Moat
Bbyvj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CELC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$14.61
Day Range
$14.4715.28
52-Week Range
$8.3922.19
Bid/Ask
$14.85 / $15.83
Market Cap
$522.66 Mil
Volume/Avg
669,144 / 236,997

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
55

Comparables

Valuation

Metric
CELC
ABOS
PRLD
Price/Earnings (Normalized)
Price/Book Value
3.430.531.01
Price/Sales
Price/Cash Flow
Price/Earnings
CELC
ABOS
PRLD

Financial Strength

Metric
CELC
ABOS
PRLD
Quick Ratio
10.6429.8311.44
Current Ratio
11.2330.2011.64
Interest Coverage
−13.89
Quick Ratio
CELC
ABOS
PRLD

Profitability

Metric
CELC
ABOS
PRLD
Return on Assets (Normalized)
−40.23%−19.28%−39.87%
Return on Equity (Normalized)
−56.35%−21.04%−44.79%
Return on Invested Capital (Normalized)
−44.81%−24.75%−43.35%
Return on Assets
CELC
ABOS
PRLD
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WpxnrqwxjtZfd$629.2 Bil
Vertex Pharmaceuticals Inc
VRTX
LpfjwhpfyKsjzlqn$120.6 Bil
Regeneron Pharmaceuticals Inc
REGN
FkgsrqpbSyxxshp$114.5 Bil
Moderna Inc
MRNA
PfcxbhnPdvk$51.1 Bil
argenx SE ADR
ARGX
WtqycydVntr$22.7 Bil
BioNTech SE ADR
BNTX
MtfhybqNkpr$20.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
XzqbckglMrdlph$19.5 Bil
Biomarin Pharmaceutical Inc
BMRN
GvqhfrwryDnpbvp$16.0 Bil
United Therapeutics Corp
UTHR
RnqnlywQkxl$13.6 Bil
Incyte Corp
INCY
JxxtrxtkDkdzmbs$12.1 Bil

Sponsor Center